The time has come for new, more precise guidelines in the treatment of high-risk acute coronary syndromes with heparin

Circulation Journal

Volumn 72, Issue 10, 2008, Pages 1674-1679

  Motovska, Zuzana ^a   Widimsky, Petr ^a   Petr, Robert ^a   Andrasova, Andrea ^a   Bilkova, Dana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antithrombin therapy; Heparin dose regimen; Non ST acute coronary syndrome

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; DRUG DOSE REGIMEN; DRUG OVERDOSE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HEPARINIZATION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; SEX DIFFERENCE; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BODY MASS INDEX; BODY WEIGHT; CORONARY CARE UNITS; CREATININE; CZECH REPUBLIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPARIN; HUMANS; KIDNEY FUNCTION TESTS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SEX CHARACTERISTICS;

EID: 52749093829     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-07-1083     Document Type: Article

References (22)

1. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-1840.
2. Braunwald E, Antman EM, Beasely JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Summary article. Circulation 2002; 106: 1893-1900.
3. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
4. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, et al, CRUSADE Investigators. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292: 2096-2104.
5. Yui Y, Hirayama A, Nonogi H, Kimura K, Kodama K, Hosoda S, et al. Unstable angina and non-ST elevation acute coronary syndrome: Epidemiology and current management in Japan (Japan Multicenter Investigation for Cardiovascular Disease-D (JMIC-D) Committee). Circ J 2007; 71: 1335-1347.
6. Bijsterveld NR, Moons AH, Meijers JC. Rebound thrombin generation after heparin therapy in unstable angina: A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002; 39: 811-817.
7. Yip HK, Chang LT, Sun CK, Chen MC, Yang CH, Hung WC, et al. Platelet activity is a biomarker of cardiac necrosis and predictive of untoward clinical outcomes in patients with acute myocardial infarction undergoing primary coronary stenting. Circ J 2006; 70: 31-36.
8. Di Nisio M, Bijsterveld NR, Meijers JC. Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes. J Am Coll Cardiol 2005; 46: 1582-1583.
9. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al, SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45-54.
10. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al, Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology: Guidelines for percutaneous coronary interventions. Eur Heart J 2005; 26: 804-847.
11. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl): 188S-203S.
12. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
13. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf CM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007; 116: e148-e304.
14. Cohen M, Demers C, Gurfinkel EP. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-452.
15. Anand SS, Yusuf S, Pogue J, Organization to Assess Strategies for Ischemic Syndromes Investigators. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003; 107: 2884-2888.
16. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110: 392-398.
17. de Swart CAM, Nijmeyer B, Roelofs JMM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-1258.
18. Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, et al. Anticoagulation in hospitalized patients with renal insufficiency: A comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125: 856-863.
19. Pitsavos C, Kourlaba G, Panagiotakos DB, Kogias Y, Mantas Y, Chrysohoou C, et al. Association of creatinine clearance and in-hospital mortality in patients with acute coronary syndromes: The GREECS study. Circ J 2007; 71: 9-14.
20. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM, et al, ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33-41.
21. Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: Effect of hemodialysis. Am J Kidney Dis 1994; 23: 828-835.
22. Marciniak E, Gockemen JP. Heparin-induced decrease in circulating antithrombin III. Lancet 1977; 2: 581-584.